GlobeNewsWire
22 Jun 2026, 12:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The ACCENT trial for narmafotinib in first-line advanced pancreatic cancer showed a confirmed response rate of 35% and a complete response rate of 7.8%. — Strong clinical efficacy data in a difficult-to-treat cancer is a primary driver of biotech valuation and potential FDA approval.
+0.80Preclinical data suggests narmafotinib blocks resistance pathways and enhances the activity of KRAS inhibitors in pancreatic and lung cancer. — Positioning the drug as a necessary companion to the emerging KRAS inhibitor class opens significant partnership and market expansion opportunities.
+0.60The FDA has granted narmafotinib both Fast Track and Orphan Drug designations. — These designations accelerate the regulatory timeline and provide market exclusivity benefits, reducing time-to-revenue.
+0.40Continue reading
6 related stories
Search tags
Amplia is actively pursuing partnership conversations with pharmaceutical and biotechnology companies for combination therapy development. — A strategic partnership with a larger firm would provide non-dilutive capital and validation, though no deal is yet signed.
+0.30Which stocks this story touches
The company reports positive Phase 3 benchmarks for narmafotinib and strong strategic positioning for combination therapies.
The company's drug daraxonrasib showed pivotal Phase 3 data doubling overall survival in pancreatic cancer.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
